CNS Drugs provides researchers and healthcare professionals with essential information on the most important aspects of drug therapies used for the management of neurological and psychiatric disorders.

Via a program of reviews and original research articles, the journal addresses major issues relating to drug therapy of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of neurological and psychiatric disorders; and the practical management of specific clinical situations.

CNS Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

There are no publication charges for standard publishing in CNS Drugs; the journal offers the option of Open Access publication via Springer Open Choice (article processing charge €3,060 / US$3,860). Please click on the link below under ‘Publishing model’ for further information about this service.

Journal information

Editors
  • Kate Palmer,
  • Susan Pochon
Publishing model
Hybrid. Open Access options available

Journal metrics

4.192 (2018)
Impact factor
4.629 (2018)
Five year impact factor
29 days
Submission to first decision
102 days
Submission to acceptance
260,008 (2019)
Downloads

Latest articles

About this journal

Electronic ISSN
1179-1934
Print ISSN
1172-7047
Abstracted and indexed in
  1. BIOSIS
  2. CNKI
  3. Chemical Abstracts Service (CAS)
  4. Current Contents/ Life Sciences
  5. Current Contents/Clinical Medicine
  6. EBSCO Academic Search
  7. EBSCO Advanced Placement Source
  8. EBSCO Biomedical Reference Collection
  9. EBSCO CINAHL
  10. EBSCO Discovery Service
  11. EBSCO Psychology & Behavioral Sciences Collection
  12. EBSCO Rehabilitation & Sports Medicine Source
  13. EBSCO SPORTDiscus
  14. EBSCO STM Source
  15. EMBASE
  16. Google Scholar
  17. Institute of Scientific and Technical Information of China
  18. Japanese Science and Technology Agency (JST)
  19. Journal Citation Reports/Science Edition
  20. Medline
  21. Naver
  22. OCLC WorldCat Discovery Service
  23. Pathway Studio
  24. ProQuest Biological Science Database
  25. ProQuest Calcium and Calcified Tissue Abstracts
  26. ProQuest Central
  27. ProQuest Health & Medical Collection
  28. ProQuest Health Research Premium Collection
  29. ProQuest Medical Database
  30. ProQuest Natural Science Collection
  31. ProQuest Neurosciences Abstracts
  32. ProQuest Psychology Database
  33. ProQuest SciTech Premium Collection
  34. ProQuest-ExLibris Primo
  35. ProQuest-ExLibris Summon
  36. PsycINFO
  37. Psyndex
  38. Reaxys
  39. SCImago
  40. SCOPUS
  41. Science Citation Index
  42. Science Citation Index Expanded (SciSearch)
  43. Semantic Scholar
Copyright information

Rights and permissions

Springer policies

© Springer Nature Switzerland AG